Sofinnova Investments

The firm sources therapeutic-company opportunities across the United States and Europe, leveraging a network built since its 1976 founding in Paris and its later independent U.S. presence. Board members and investment professionals originate deals through academic medical centers, biotech clusters, and relationships with serial life-science entrepreneurs. The dual-continent footprint gives it visibility into both FDA-oriented and EMA-oriented clinical-stage programs.

Sofinnova Investments is a venture capital and public-equity asset manager, not a family office. The firm raises capital from external limited partners and deploys it through dedicated life-science funds. Its most recent flagship vehicle, Sofinnova Venture Partners X, closed at $650 million.

Yes, the firm operates a public-equity strategy focused on global therapeutics, complementing its core venture-capital activity. The public-equity effort invests in biopharmaceutical companies that are already listed, while the venture funds focus on private, clinical-stage drug developers.

The two firms share a common origin: Sofinnova was founded in Paris in 1976. In the 2000s, the global organization restructured into separate management companies — Sofinnova Investments based in the United States and Sofinnova Partners based in Paris. They now operate as independent entities with distinct fund families and investment teams.

Sofinnova Investments concentrates on late-preclinical and clinical-stage therapeutics and has been primarily focused on drugs over the last decade. The firm does not list medical-device, diagnostics, or healthcare-services companies among its active portfolio, steering its capital toward areas such as oncology, neurology, ophthalmology, and rare disease.

Sofinnova invests in both private and public equity companies. For private companies, the firm typically takes equity positions through its venture-capital funds and seeks board representation to guide development, regulatory strategy, and eventual IPO or M&A exits.

Sofinnova reports having funded 118 portfolio companies. Outcomes include initial public offerings — such as Seaport Therapeutics and BioAge Labs — and strategic acquisitions by large pharmaceutical companies including AstraZeneca, Roche, and Bristol Myers Squibb. The firm does not publicly disclose internal rates of return or distributed-to-paid-in multiples.